Bioversys

Basel, Switzerland. January 12, 2021. 09:00 CEST BioVersys is proud to announce together with its partner GSK the first dosing of our Tuberculosis asset BVL-GSK098 in clinical Phase I. This is a great achievement for this groundbreaking program. For the first time, a small molecule targeting bacterial transcriptional regulators, is clinically assessed. We would like […]

Basel, Switzerland. November 18, 2021. 09:00 CEST BioVersys has reached a major milestone by entering clinical development with the start of Phase 1 testing of BV100 in healthy volunteers. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focused on developing small molecules for multidrug-resistant bacterial infections with applications in AntiMicrobial Resistance (AMR) and targeted

Basel, Switzerland. September 1, 2020. 09:00 CEST BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candidates into first in human clinical trials and has also strengthened its board with the appointment of Dr. Eduard Holdener. BioVersys AG, a privately owned,

Basel, Switzerland, July 14th, 2020. 09:00 CEST BioVersys and partners, the Institut Pasteur de Lille and the University of Lille, from Région Hauts-de-France, sign a long-term collaboration agreement creating a unique cross-border cluster of research excellence focused on unmet medical needs in antimicrobial resistance. BioVersys continues to strengthen ties with two institutes of scientific excellence,

BVL-GSK098 IS BEING DEVELOPED FOR THE TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS INFECTIONS Basel, Switzerland. June, 23 rd , 2020. 09:00 CEST BioVersys develops BVL-GSK098, in collaboration with GSK, as an entirely new mechanism to potentiate and overcome resistance of ethionamide in tuberculosis. BioVersys AG a privately owned, multi-asset Swiss pharmaceutical company focusing on research and

Basel, Switzerland. May 5th, 2020. 09:00 CEST The Global Antibiotic Research and Development Partnership (GARDP) has today announced an agreement with Swiss biopharmaceutical company BioVersys to explore opportunities to accelerate the research and development of antibiotics for serious bacterial infections. The Memorandum of Understanding includes supporting BioVersys in the preparation of a paediatric investigational plan

FOR DEVELOPMENT OF FIRST-IN-CLASS STAND-ALONE ANTI-VIRULENCE SMALL MOLECULE DRUGS – A PARADIGM SHIFT IN AMR THERAPY Basel, Switzerland, October 29, 2019. 09:00 CET CARB-X funds BioVersys up to US$ 8.92 million to support the development of first-in-class anti-virulence small molecule drugs that disarm bacteria, opening the door for a paradigm shift in AMR therapy. BioVersys

Basel, Switzerland, June 20, 2019. 13:00 CET BioVersys has been awarded EUR 6.92 Million funding for TRIC-TB from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853800. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. BioVersys is pleased to announce that it has

Basel, Switzerland, May 27, 2019. 09:00 CET BioVersys Receives QIDP Designation from the U.S. FDA for the Development of BV100 BioVersys AG a privately owned, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, announced today that its